(NASDAQ: TPST) Tempest Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 75.85%.
Tempest Therapeutics's earnings in 2026 is -$36,054,000.On average, 3 Wall Street analysts forecast TPST's earnings for 2026 to be -$12,499,941, with the lowest TPST earnings forecast at -$12,009,747, and the highest TPST earnings forecast at -$12,867,587. On average, 3 Wall Street analysts forecast TPST's earnings for 2027 to be -$10,326,038, with the lowest TPST earnings forecast at -$9,921,096, and the highest TPST earnings forecast at -$10,629,745.
In 2028, TPST is forecast to generate -$71,965,241 in earnings, with the lowest earnings forecast at -$69,143,075 and the highest earnings forecast at -$74,081,866.